Omnicell, Inc. (OMCL): Price and Financial Metrics


Omnicell, Inc. (OMCL)

Today's Latest Price: $86.55 USD

2.20 (-2.48%)

Updated Oct 30 4:00pm

Add OMCL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 70 in Medical - Services

See all "A" rated Strong Buy stocks

OMCL Stock Summary

  • OMCL's current price/earnings ratio is 75.4, which is higher than 89.9% of US stocks with positive earnings.
  • With a year-over-year growth in debt of -64.57%, OMNICELL Inc's debt growth rate surpasses merely 3.81% of about US stocks.
  • In terms of volatility of its share price, OMCL is more volatile than merely 12.93% of stocks we're observing.
  • Stocks that are quantitatively similar to OMCL, based on their financial statements, market capitalization, and price volatility, are TWOU, IRTC, ATRC, VCYT, and QTRX.
  • Visit OMCL's SEC page to see the company's official filings. To visit the company's web site, go to www.omnicell.com.

OMCL Stock Price Chart Interactive Chart >

Price chart for OMCL

OMCL Price/Volume Stats

Current price $86.55 52-week high $94.85
Prev. close $88.75 52-week low $54.24
Day low $85.85 Volume 492,900
Day high $89.34 Avg. volume 352,675
50-day MA $75.55 Dividend yield N/A
200-day MA $72.81 Market Cap 3.70B

Omnicell, Inc. (OMCL) Company Bio


Omnicell provides automation and business analytics software for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. The company was founded in 1992 and is based in Mountain View, California.

OMCL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$86.55$40.64 -53%

We started the process of determining a valid price forecast for OMNICELL Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that OMNICELL Inc ranked in the 28th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for OMCL, they are:

  • The company's balance sheet shows it gets 99% of its capital from equity, and 1% of its capital from debt. Its equity weight surpasses that of 89.31% of free cash flow generating stocks in the Technology sector.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately just 6.27% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • OMCL's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 51.19% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-54%
1%-53%
2%-53%
3%-52%
4%-52%
5%-51%

For other companies in the Technology that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as OMCL, try INOD, BLKB, MIME, NXPI, and CCMP.


OMCL Latest News Stream


Event/Time News Detail
Loading, please wait...

OMCL Latest Social Stream


Loading social stream, please wait...

View Full OMCL Social Stream

Latest OMCL News From Around the Web

Below are the latest news stories about OMNICELL Inc that investors may wish to consider to help them evaluate OMCL as an investment opportunity.

Omnicell to Release Third Quarter 2020 Earnings Results on October 27, 2020

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2020 Earnings Results on October 27, 2020

Business Wire | September 29, 2020

Omnicell prices $500M 0.25% convertible senior notes offering

Omnicell (OMCL) has priced $500M of 0.25% convertible senior unsecured notes due September 15, 2025 (up 37.5% Conversion Premium) in a private placement. Initial purchasers of the notes will have an option to purchase up to an additional $75M notes. Closing date is September 25, 2020. Interest will be payable semi-annually in...

Seeking Alpha | September 23, 2020

Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior Notes

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior Notes

Business Wire | September 22, 2020

Peninsula Regional Medical Center Extends Partnership With Omnicell to Enhance Safety and Efficiency in Sterile Compounding

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Peninsula Regional Medical Center Extends Partnership with Omnicell to Enhance Safety and Efficiency in Sterile Compounding

Business Wire | August 17, 2020

Omnicell scoops up PSG's 340B business for $225M

Omnicell (OMCL) has agreed to acquire Pharmaceutical Strategies Group’s ((PSG)) 340B Link business for $225M in cash.The acquisition expands Omnicell’ pharmacy supply chain capabilities for efficient, compliant management of 340B drug pricing program340B Link business posted annual revenues of ~$35MThe deal is expected to be immediately accretive to non- GAAP earnings per...

Seeking Alpha | August 12, 2020

Read More 'OMCL' Stories Here

OMCL Price Returns

1-mo 15.32%
3-mo 23.13%
6-mo 20.83%
1-year 21.85%
3-year 76.45%
5-year 206.70%
YTD 5.91%
2019 33.44%
2018 26.27%
2017 43.07%
2016 9.07%
2015 -6.16%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8567 seconds.